Hybio Pharmaceutical

Hybio Pharmaceutical Co., Ltd. is a high-tech enterprise focused on the research, development, and manufacturing of a wide range of peptide products. Established in 1998, Hybio has grown to become one of the largest and most professional peptide pharmaceutical companies in China. The company operates in the pharmaceutical industry, specifically targeting the peptide sector, which involves short chains of amino acids used in various medical treatments. Hybio serves a diverse clientele, including hospitals, research institutions, and pharmaceutical companies, both domestically and internationally.

Hybio's business model revolves around the production and sale of peptide finished dosage products, peptide active pharmaceutical ingredients (APIs), and providing contract research and manufacturing services (CRO/CMO). The company generates revenue through the direct sale of its peptide products and by offering specialized services to other pharmaceutical companies.

Hybio's market presence is bolstered by its comprehensive product range and its commitment to innovation and quality. The company has received numerous accolades, including being listed in Forbes China and winning the Shield Award. Hybio's participation in global events such as the AAPS Annual Meeting and CPHI Worldwide further underscores its prominence in the industry.

Keywords: peptide, pharmaceutical, R&D, manufacturing, APIs, CRO, CMO, China, innovation, quality.